Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

At the 2021 Annual General Meeting of Shareholders (the "Annual Meeting") of Osmotica Pharmaceuticals plc (the "Company") held on June 17, 2021, the Company's shareholders approved an amendment and restatement of the Company's 2018 Incentive Plan (as amended and restated, the "Amended 2018 Plan") to (i) increase the number of ordinary shares, $0.01 nominal value per share ("Ordinary Shares"), authorized for issuance under the plan from 4,100,000 to 9,100,000, (ii) remove certain provisions relating to Section 162(m) of the U.S. Internal Revenue Code of 1986, as amended, that are no longer applicable following the elimination of the performance-based compensation exception to Section 162(m)'s limitation on deductibility by the Tax Cuts and Jobs Act of 2017, and (iii) extend the term of the plan until June 17, 2031.

The description of the Amended 2018 Plan under the heading "Proposal 4, Approval of the Amended and Restated 2018 Incentive Plan" contained in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2021 is incorporated herein by reference. A copy of the Amended 2018 Plan is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Annual Meeting held on June 17, 2021, the Company's shareholders voted on the following proposals:





   ·  Election of the directors of the Company, each to serve a term extending
      until the conclusion of the Company's next annual general meeting of
      shareholders;





   ·  Ratification, in a non-binding advisory vote, of the appointment of Ernst &
      Young LLP as the independent registered public accounting firm of the
      Company for the year ending December 31, 2021, and authorization, in a
      binding vote, of the Company's board of directors, acting through the audit
      committee, to set the independent registered public accounting firm's
      remuneration;





   ·  Approval of a waiver of offer obligations under Rule 37 of the Irish
      Takeover Rules to enable share buybacks or redemptions; and





   ·  Approval of the Amended 2018 Plan, which, among other things, increases the
      number of Ordinary Shares authorized for issuance under the plan from
      4,100,000 to 9,100,000.

The final voting results for the Annual Meeting are as follows:

1. The Company's shareholders elected Brian Markison, Joachim Benes, David


    Burgstahler, Gregory L. Cowan, Michael DeBiasi, Sriram Venkataraman, Juan
    Vergez and Fred Weiss as directors, each to serve a term extending until the
    conclusion of the Company's next annual general meeting of shareholders or
    until his successor is duly elected and qualified or until his death,
    resignation or removal, based on the following votes:




                                                                         Broker
                          For            Against         Abstain        Non-Votes
Brian Markison          47,989,668       2,668,002         156,695       6,374,410

Joachim Benes           47,068,347       2,620,333       1,125,685       6,374,410

David Burgstahler       46,808,935       3,742,931         262,499       6,374,410

Gregory L. Cowan        49,373,869         289,038       1,151,458       6,374,410

Michael DeBiasi         49,404,715         275,855       1,133,795       6,374,410

Sriram Venkataraman     47,969,290       2,616,223         228,852       6,374,410

Juan Vergez             46,553,686       3,080,920       1,179,759       6,374,410

Fred Weiss              49,137,780         547,317       1,129,268       6,374,410

2. The Company's shareholders ratified, in a non-binding advisory vote, the


    appointment of Ernst & Young LLP as the independent registered public
    accounting firm of the Company for the year ending December 31, 2021, and
    authorized, in a binding vote, the Company's board of directors, acting
    through the audit committee, to set the independent registered public
    accounting firm's remuneration, based on the following votes:




   For       Against   Abstain
56,993,734   85,029    110,012

3. The independent shareholders approved a waiver of offer obligations under Rule


    37 of the Irish Takeover Rules to enable share buybacks or redemptions, based
    on the following votes:




   For        Against    Abstain
11,457,687   3,919,503   912,102

4. The Company's shareholders approved the Amended 2018 Plan to, among other


    things, increase the number of Ordinary Shares authorized for issuance under
    the plan from 4,100,000 to 9,100,000, based on the following votes:




   For        Against    Abstain   Broker Non-Votes
47,130,663   3,513,859   169,843      6,374,410

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.    Description
  99.1           Osmotica Pharmaceuticals plc Amended and Restated 2018 Incentive Plan

© Edgar Online, source Glimpses